GlassScriptPhysician profile
Andrew Matthews
NPI 1528405271
$1,516.72
in general payments reported to CMS, 2019-2025
19 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $86.09 · 2021: $212 · 2022: $277 · 2023: $156 · 2024: $314 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $441.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $164.18 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $155.94 | 2019-2025 | |
| Lilly USA, LLC | $147.66 | 2020-2024 | Jardiance |
| Amgen INC. | $114.96 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $86.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $78.97 | 2019-2025 | Gardasil 9, Capvaxive, Dificid |
| Astrazeneca Pharmaceuticals LP | $61.29 | 2021-2025 | Fasenra, Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.30 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.14 | 2025 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $31.63 | 2024-2025 | Horizant |
| Dynavax Technologies Corporation | $30.63 | 2020-2024 | Heplisav-B |
| Daiichi Sankyo INC. | $27.85 | 2020 | |
| Ossur Americas, INC. | $23.36 | 2024 | Miami J |
| Ultragenyx Pharmaceutical INC. | $18.09 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.00 | 2024 | Arexvy |
| Gilead Sciences, INC. | $15.00 | 2022 | |
| Almatica Pharma LLC | $13.64 | 2021 | |
| La Jolla Pharmaceutical Company | $13.10 | 2024 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.